Taken together, we suggest that tumor-suppressive effect of PARP1 inhibition is mediated, at least in part, by FOXO3A activation, although further studies might be required to address direct signaling mechanisms between PARP1 and FOXO3A. The gene discussed is PARP1; the disease is neoplasm.